As Some VCs Run On Empty, Others Are Topping Off The Tank

 
• By Paul Bonanos
  
Generate a summary of this article
Listen to this article
Beta

New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.

As liquidity remains scarce and long-term returns from venture funds are at best proving lukewarm, some limited partners are losing confidence in the venture capital model. For biotech and health care-oriented venture, new money is increasingly hard to come by, with smaller commitments from pension funds, university endowments and other traditional suppliers of capital. ( See "Biotech Backers Are Learning to Live with Exit-by-Earn-out," START-UP , March 2010 Also see "Biotech Backers Are Learning to Live with Exit-by-Earn-out " - Scrip, 1 March, 2010..) With increasing frequency, firms are capping their newest funds short of already-reduced expectations.

Among the latest to aim for a more modest fund is Polaris Venture Partners, which has raised the first $233...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.